Axon Enterprise

AXON

----

2026-W372026-09-07

AXON.US Weekly Report · 2026-W37

AXON.US declined sharply this week by 7%, hitting its lowest point since mid-August. The core trigger is Q2 earnings deterioration—while revenue grew 35% year-over-year, net profit margin halved from 21% in Q1 to 3.3%, and EPS crashed 82% sequentially. Institutional ratings remain constructive (18 buy-equivalent votes), yet this week saw broad capital outflows, indicating the market is more sensitive to near-term profit compression than bullish analyst calls suggest.

Price Action & Technical

This week closed at 479.34 USD, down 36.33 USD from the prior Friday close (Sept 4) of 515.67, representing a -7.04% decline. Weekly range extended from 514.62 (high, Sept 8) to 473.25 (low, Sept 11), a 8.03% swing.

Four trading days accumulated 3.03 million shares traded, significantly below the 60-day median of 700–1,200 million shares per day, displaying a volume-contracting decline—selling pressure exists but stopped short of panic dumping. Turnover rate: 0.79%, at the lower end.

Valuation Positioning

Price-to-Book (P/B): 10.6x
Per valuation data, current P/B sits around the 45th percentile over the past three years (below median), while industry median stands at 3.53. AXON.US’s P/B remains materially above industry peers in absolute terms.

Price-to-Earnings (P/E): 195.4x
This figure is distorted due to Q2 EPS compression; the elevated multiple is a statistical artifact rather than a valuation signal. Watch for recovery in coming quarters.

Earnings Realization

Q2 2026 Results vs. Consensus:

EPS: 0.36 USD (YoY -18.18%; QoQ Q1 2.05 USD, down 82.4%)
Operating Revenue: 904.4M USD (YoY +35.28%)
Net Profit: 29.4M USD (YoY -18.52%; QoQ Q1 169.3M USD, down 82.6%)
Net Margin: 3.25% (QoQ Q1 20.97%, steep decline)

Revenue growth persists but profitability collapsed, suggesting cost or expense growth outpaced top-line gains. This earnings shock triggered this week’s sell-off.

Consensus Forward Outlook:
Full-year EPS consensus: 8.98 USD. Current trajectory risks missing this target if margin pressure persists. Prior four quarters: -0.03 (Q3 2025), 0.44 (Q2 2025), 2.05 (Q1 2026), 0.36 (Q2 2026)—extreme volatility raises earnings quality concerns.

Capital Flows

Broad capital outflows across all participant tiers this week:

Large Funds: Net outflow (Inflow 48.32 vs Outflow 76.87, net -28.55)
Mid-size: Net outflow (Inflow 504.35 vs Outflow 575.70, net -71.35)
Retail: Net outflow (Inflow 1583.04 vs Outflow 1724.67, net -141.63)

All three layers sold; large institutions proportionally outnumbered buyers, retail sold in absolute quantity. This diverges sharply from the constructive institutional rating consensus, evidencing a gap between asset managers’ published views and active traders’ behavior.

Institutional Views

Rating Distribution (as of Sept 11):

Strong Buy: 10 analysts
Buy: 8 analysts
Hold: 3 analysts
No Rating: 1 analyst
Coverage: 22 analysts

Price Targets:

Mean Target: 706.21 USD (vs. current 479.34 USD, +47.3% upside)
Highest: 830 USD
Lowest: 440 USD

Institutional ratings show a timeliness lag—current calls largely reflect Q1’s strong beat, while Q2’s profit deterioration is not yet absorbed into published targets. Ratings typically lag price by 2–4 weeks; this week’s sharp decline will likely force target revisions.

Weekly News Highlights

Core themes distilled:

ALPR Contract Migration & Reaffirmation — Axon’s competitive standing in automated license plate recognition faces city contract transitions, yet multiple analysts reaffirm the strategy; long-term thesis unchanged despite near-term head winds.
CEO Equity Sale Signal — CEO Patrick W. Smith sold 10,000 shares (value: 5.08M USD) this week. Signal ambiguity: profit-taking at peaks vs. routine portfolio rebalancing. Requires scrutiny of net share position trend.
Institutional Buying on Weakness — Manulife Financial, Parkside Financial add positions, signaling institutional appetite for a bottom. Yet this may lag the panic inflection point by weeks.

Top 10 Recent News Items (reverse chronological):

Contradictions & Coherence

Three Critical Contradictions:

Valuation vs. Profitability: Low P/B (45th percentile) should imply “cheap,” yet P/E is distorted and Q2 profit collapsed. The “cheapness” label is a mirage.
Ratings vs. Capital Flows: 18 analysts constructive (47% upside to target), yet all participant tiers posted net selling. Market has rejected the bullish narrative, or analyst calls are anchored to obsolete (Q1) data.
Earnings Magnitude vs. Price Decline: EPS and net margin both fell >80% sequentially, yet stock down only 7% this week. If profit erosion persists (not one-off), further downside likely awaits.

Coherent Signal:
Near-term markets are repricing Q2 profit shock; capital and price have already moved. Institutional ratings not yet reset; next revision window opens at Q3 guidance (typically mid-October). This week marks a short-term bottom probe post-Q2 shock; Q3 trajectory on margin recovery is the key inflection.